A randomised controlled trial of TNK-tPA versus standard of care for minor ischemic stoke with proven occlusion
Lead PI: Prof Mark Parsons
No. of Patients Currently Recruited: 139 No. of Patients Required: 1274
TEMPO-2 is a prospective randsomised open label, blinded, multicentre, controlled (PROBE) trial of thrombolysis with low dose Tenecteplase compared to standard of care in the prevention of disability at 3 months in minor ischemic stroke with proven acute symptomatic occlusion.TEMPO-2 is examining the role of thrombolysis with low-dose (0.25mg/kg) tenecteplase for patients with minor stroke (NIHSS 0-5) and proven intracranial occlusion (defined by CTA or CTP) in reducing disability at 90 days after stroke onset. The study will enrol up to 1274 patients in Canada, Europe and Australia.